Jul. 11 at 4:28 PM
$PDSB all frustration aside the filing was not negative. They were just registering shares issued as part of the 6/15 closing. best explanation remains that the financing was designed to bridge to a catalyst. PDS now has several financing tools:
$6 million convertible note,
warrants,
an ATM facility.
IMO, that combo suggests PDS wanted to ensure liquidity rather than immediately pursue a much larger, highly dilutive raise. This is common, creating financing flexibility before meaningful clinical milestones. We just need the announcement of a deal already. I feel very confident the annual meeting was pushed back to allow for closure of a transaction.
